Direct-to-Brain attack on deadly breast cancer spread
NCT ID NCT01373710
Summary
This study tested whether delivering the breast cancer drug trastuzumab (Herceptin) directly into the spinal fluid could help patients whose cancer had spread to the membranes around the brain and spinal cord. The trial involved 34 people with advanced HER2-positive breast cancer that had developed this serious complication. Researchers first determined a safe dose, then looked at whether this direct delivery method could delay neurological problems and control the cancer in the nervous system.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Grenoble
Grenoble, 38700, France
-
François Baclesse Center
Caen, Calvados, 14076, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Curie - Claudius Regaud Hospital
Paris, Île-de-France Region, 75248, France
-
Institut Univesitaire du Cancer de Toulouse
Toulouse, 31100, France
-
Institut du Cancer de Montpellier
Montpellier, 34298, France
-
Léon Bérard Center
Lyon, Rhone, 69373, France
-
Oscar Lambret Center
Lille, Nord, 59020, France
-
Pitie Salpetriere Hospital
Paris, Île-de-France Region, 75651, France
-
Rene Huguenin Hospital
Saint-Cloud, Haut de Seine, 92210, France
Conditions
Explore the condition pages connected to this study.